COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
The current price of CMPS is $6.61 USD — it has decreased by -1.2% in the past 24 hours. Watch Compass Pathways stock price performance more closely on the chart.
What is Compass Pathways stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Compass Pathways stocks are traded under the ticker CMPS.
Is Compass Pathways stock price growing?▼
CMPS stock has fallen by -5.44% compared to the previous week, the month change is a +0.92% rise, over the last year Compass Pathways has showed a +53.36% increase.
What were Compass Pathways earnings last quarter?▼
CMPS earnings for the last quarter are -0.41 USD per share, whereas the estimation was -0.38 USD resulting in a -7.89% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Compass Pathways revenue for the last year?▼
Compass Pathways revenue for the last year amounts to 0 USD.
What is Compass Pathways net income for the last year?▼
CMPS net income for the last year is -310.24M USD.
How many employees does Compass Pathways have?▼
As of February 03, 2026, the company has 166 employees.
In which sector is Compass Pathways located?▼
Compass Pathways operates in the Health Care sector.
When did Compass Pathways complete a stock split?▼
Compass Pathways has not had any recent stock splits.